2019
An Advanced Practice Practitioner–Based Program to Reduce 30‐ and 90‐Day Readmissions After Liver Transplantation
Mahmud N, Halpern S, Farrell R, Ventura K, Thomasson A, Lewis H, Olthoff KM, Levine MH, Nazarian S, Khungar V. An Advanced Practice Practitioner–Based Program to Reduce 30‐ and 90‐Day Readmissions After Liver Transplantation. Liver Transplantation 2019, 25: 901-910. PMID: 30947393, PMCID: PMC6548546, DOI: 10.1002/lt.25466.Peer-Reviewed Original ResearchMeSH KeywordsAgedEnd Stage Liver DiseaseFemaleHumansLiver TransplantationMaleMiddle AgedNurse PractitionersPatient ReadmissionPilot ProjectsPostoperative CarePostoperative ComplicationsProfessional RoleProgram EvaluationRetrospective StudiesRisk FactorsSex FactorsTime FactorsTreatment OutcomeUnited StatesConceptsLiver transplantationReadmission ratesRisk factorsPostexposure groupCare programIndex hospitalization characteristicsRetrospective cohort studyRisk of readmissionHigher readmission ratesAssociated risk factorsAdvanced practice practitionersIndex hospitalizationAnalytic cohortCohort studyHospitalization characteristicsReferral centerHospital readmissionLT centersAdjusted analysisMale sexNurse practitionersReadmissionClinic availabilitySignificant differencesPatients
2017
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study. Hepatology 2017, 66: 1090-1101. PMID: 28504842, PMCID: PMC5756478, DOI: 10.1002/hep.29258.Peer-Reviewed Original ResearchConceptsSustained virologic responseOmbitasvir/paritaprevir/ritonavirParitaprevir/ritonavirTransplant recipientsLiver transplantKidney transplantAntiviral therapyLarge prospective observational cohort studyChronic hepatitis C virusLiver-kidney transplant recipientsProspective observational cohort studySolid organ transplant recipientsHepatitis C virus (HCV) treatmentBaseline total bilirubinHCV-TARGET studyPrior antiviral therapyAbsence of cirrhosisKidney transplant recipientsLiver transplant recipientsObservational cohort studyOrgan transplant recipientsC virus treatmentGlomerular filtration rateCessation of treatmentSOF/ledipasvir